1-7 of 7
Nuriet K Khuageva
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Jesús F San Miguel, MD PhD, Rudolf Schlag, MD, Nuriet K Khuageva, MD, Meletios Athanasios Dimopoulos, MD, Ofer Shpilberg, MD, MPH, Martin Kropff, MD, Ivan Spicka, MD, PhD, Maria T Petrucci, Antonio Palumbo, MD, Olga S Samoilova, MD, Anna Dmoszynska, Kudrat M Abdulkadyrov, Prof, Michel Delforge, MD, PhF, Bin Jiang, María-Victoria Mateos, MD, PhD, Kenneth C. Anderson, MD, Dixie-Lee Esseltine, MD, FRCPC, Kevin Liu, PhD, William M Deraedt, PhD, Andrew Z Cakana, MD, FRCPath, Helgi van de Velde, MD, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 476.
https://doi.org/10.1182/blood.V118.21.476.476
Published: 2011
Journal Articles

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, Nuriet K Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Spicka, Maria Teresa Petrucci, Antonio Palumbo, MD, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Dixie-Lee Esseltine, Kevin Liu, Andrew Z Cakana, Helgi van de Velde, Jesús F. San Miguel
Journal: Blood
Blood (2009) 114 (22): 3859.
https://doi.org/10.1182/blood.V114.22.3859.3859
Published: 2009
Journal Articles

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Clinical Trials & Observations
Jean-Luc Harousseau, Giovanni Martinelli, Wieslaw W. Jedrzejczak, Joseph M. Brandwein, Dominique Bordessoule, Tamas Masszi, Gert J. Ossenkoppele, Julia A. Alexeeva, Gernot Beutel, Johan Maertens, Maria-Belen Vidriales, Hervé Dombret, Xavier Thomas, Alan K. Burnett, Tadeusz Robak, Nuriet K. Khuageva, Anatoly K. Golenkov, Elena Tothova, Lars Mollgard, Youn C. Park, Annick Bessems, Peter De Porre, Angela J. Howes, for the FIGHT-AML-301 Investigators
Journal: Blood
Blood (2009) 114 (6): 1166–1173.
https://doi.org/10.1182/blood-2009-01-198093
Published: 2009
Journal Articles

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Jesus F San Miguel, Rudolf Schlag, Nuriet K Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Ivan Spicka, Maria Teresa Petrucci, Antonio Palumbo, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Maria-Victoria Mateos, Kenneth C Anderson, Dixie-Lee Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Paul Richardson
Journal: Blood
Blood (2008) 112 (11): 650.
https://doi.org/10.1182/blood.V112.11.650.650
Published: 2008
Journal Articles

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

Meletios A Dimopoulos, Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin H Kropff, Maria Teresa Petrucci, Michel Delforge, Julia A Alexeeva, Rik Schots, Tamas Masszi, Maria-Victoria Mateos, William Deraedt, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesus F San Miguel
Journal: Blood
Blood (2008) 112 (11): 1727.
https://doi.org/10.1182/blood.V112.11.1727.1727
Published: 2008
Journal Articles

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Maria Teresa Petrucci, Victor A Rossiev, Jian Hou, Tadeusz Robak, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F. San Miguel
Journal: Blood
Blood (2008) 112 (11): 1741.
https://doi.org/10.1182/blood.V112.11.1741.1741
Published: 2008
Journal Articles

Imexon (AOP 99.0001) for Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study

Thomas M. Moehler, Anatoli Golenkov, MD, Heinz Ludwig, Martin H Kropff, Nuriet K Khuageva, E. A Osmanov, I. Broen, MD, H. Goldschmidt
Journal: Blood
Blood (2008) 112 (11): 5195.
https://doi.org/10.1182/blood.V112.11.5195.5195
Published: 2008